Stryker Corp. plans to sell its U.S. spinal implant business to a New York-based family office Viscogliosi Brothers LLC.

Rachel Wells is a Forbes contributor and freelance writer who covers remote and flexible working, freelancing, side hustles, skill development, and AI, for Gen Z and Millennials. She has been ...

Argus analyst David Toung raised the firm’s price target on Stryker (SYK) to $450 from $410 and keeps a Buy rating on the shares. Argus expects ...

Stryker Corporation (NYSE:SYK), a prominent player in the medical technology sector, serves over 150 million patients ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings ...

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...

Preston Wells, finance chief at its orthopaedics unit, will replace incumbent Glenn Boehnlein, effective April 1. Sales at Stryker's medical surgery and neurotechnology unit climbed 10.6% to $3.89 ...

Stryker ( (SYK)) has shared an update. On January 28, 2025, Stryker announced the retirement of Glenn S. Boehnlein from his role as Vice President, Chief Financial Officer, effective April 1, 2025.